TY - JOUR
T1 - Serum Extracellular Vesicle-Derived microRNAs as Potential Biomarkers for Pleural Mesothelioma in a European Prospective Study
AU - Casalone, Elisabetta
AU - Birolo, Giovanni
AU - Pardini, Barbara
AU - Allione, Alessandra
AU - Russo, Alessia
AU - Catalano, Chiara
AU - Mencoboni, Manlio
AU - Ferrante, Daniela
AU - Magnani, Corrado
AU - Sculco, Marika
AU - Dianzani, Irma
AU - Grosso, Federica
AU - Mirabelli, Dario
AU - Filiberti, Rosa Angela
AU - Rena, Ottavio
AU - Sacerdote, Carlotta
AU - Rodriguez-Barranco, Miguel
AU - Smith-Byrne, Karl
AU - Panico, Salvatore
AU - Agnoli, Claudia
AU - Johnson, Theron
AU - Kaaks, Rudolf
AU - Tumino, Rosario
AU - Huerta, José María
AU - Riboli, Elio
AU - Heath, Alicia K.
AU - Trobajo-Sanmartín, Camino
AU - Schulze, Matthias B.
AU - Saieva, Calogero
AU - Amiano, Pilar
AU - Agudo, Antonio
AU - Weiderpass, Elisabete
AU - Vineis, Paolo
AU - Matullo, Giuseppe
N1 - Publisher Copyright:
© 2022 by the authors.
PY - 2023/1
Y1 - 2023/1
N2 - Malignant pleural mesothelioma (MPM) is an aggressive cancer with a dismal prognosis. Early therapeutic interventions could improve patient outcomes. We aimed to identify a pattern of microRNAs (miRNAs) as potential early non-invasive markers of MPM. In a case-control study nested in the European Prospective Investigation into Cancer and Nutrition cohort, we screened the whole miRNome in serum extracellular vesicles (EVs) of preclinical MPM cases. In a subgroup of 20 preclinical samples collected five years prior MPM diagnosis, we observed an upregulation of miR-11400 (fold change (FC) = 2.6, adjusted p-value = 0.01), miR-148a-3p (FC = 1.5, p-value = 0.001), and miR-409-3p (FC = 1.5, p-value = 0.04) relative to matched controls. The 3-miRNA panel showed a good classification capacity with an area under the receiver operating characteristic curve (AUC) of 0.81 (specificity = 0.75, sensitivity = 0.70). The diagnostic ability of the model was also evaluated in an independent retrospective cohort, yielding a higher predictive power (AUC = 0.86). A signature of EV miRNA can be detected up to five years before MPM; moreover, the identified miRNAs could provide functional insights into the molecular changes related to the late carcinogenic process, preceding MPM development.
AB - Malignant pleural mesothelioma (MPM) is an aggressive cancer with a dismal prognosis. Early therapeutic interventions could improve patient outcomes. We aimed to identify a pattern of microRNAs (miRNAs) as potential early non-invasive markers of MPM. In a case-control study nested in the European Prospective Investigation into Cancer and Nutrition cohort, we screened the whole miRNome in serum extracellular vesicles (EVs) of preclinical MPM cases. In a subgroup of 20 preclinical samples collected five years prior MPM diagnosis, we observed an upregulation of miR-11400 (fold change (FC) = 2.6, adjusted p-value = 0.01), miR-148a-3p (FC = 1.5, p-value = 0.001), and miR-409-3p (FC = 1.5, p-value = 0.04) relative to matched controls. The 3-miRNA panel showed a good classification capacity with an area under the receiver operating characteristic curve (AUC) of 0.81 (specificity = 0.75, sensitivity = 0.70). The diagnostic ability of the model was also evaluated in an independent retrospective cohort, yielding a higher predictive power (AUC = 0.86). A signature of EV miRNA can be detected up to five years before MPM; moreover, the identified miRNAs could provide functional insights into the molecular changes related to the late carcinogenic process, preceding MPM development.
KW - biomarkers
KW - early changes
KW - malignant pleural mesothelioma
KW - microRNAs
KW - next generation sequencing
UR - http://www.scopus.com/inward/record.url?scp=85145992321&partnerID=8YFLogxK
U2 - 10.3390/cancers15010125
DO - 10.3390/cancers15010125
M3 - Article
SN - 2072-6694
VL - 15
JO - Cancers
JF - Cancers
IS - 1
M1 - 125
ER -